Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.04 USD
Change Today +0.0011 / 2.56%
Volume 1.6M
CBIS On Other Exchanges
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

cannabis science inc (CBIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/14 - $0.17
52 Week Low
12/1/14 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CANNABIS SCIENCE INC (CBIS)

cannabis science inc (CBIS) Related Bloomberg News

View More Bloomberg News

cannabis science inc (CBIS) Related Businessweek News

No Related Businessweek News Found

cannabis science inc (CBIS) Details

Cannabis Science, Inc. develops, produces, and commercializes phytocannabinoid-based pharmaceutical products. It develops medicines to treat autism, blood pressure, cancer and cancer side effects, and other illnesses, including general health maintenance. The company is developing CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains; CS-S/BCC-1 for basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, it provides an online video-based medical cannabis education system comprising various courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending. The company has a license agreement with Apothecary Genetics Investments LLC. to produce various brand formulations for California medical cannabis market. Cannabis Science, Inc. is based in Colorado Springs, Colorado.

1 Employees
Last Reported Date: 04/23/14

cannabis science inc (CBIS) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: --
Co-Founder, Chief Operating Officer, General ...
Total Annual Compensation: $60.0K
Chief Financial Officer and Director
Total Annual Compensation: $30.0K
President of European Operations and Director
Total Annual Compensation: $22.5K
Chief Scientific Officer
Total Annual Compensation: $22.0K
Compensation as of Fiscal Year 2013.

cannabis science inc (CBIS) Key Developments

Allen A. Herman Joins Cannabis Science, Inc.'s Scientific Advisory Board

Cannabis Science, Inc. announced that Allen A. Herman has joined its scientific advisory board. He was the founding Dean of the Republic of South Africa's National School of Public Health. Dr. Herman also served as scientific advisor to then deputy-president (and now president) of the Republic of South Africa, Jacob Zuma and the South African Minister of Defense in the design and execution of a substantial HIV/AIDS treatment program for the South African National Defense Force. Dr. Herman will report directly to the President & CEO, Mr. Raymond C. Dabney to assist him in tracking and monitoring the multiple international drug development programs the company has underway.

Cannabis Science, Inc. Names Raymond C. Dabney as Vice Chair of the CFA Africa Healthcare Infrastructure Initiative Committee

Cannabis Science, Inc. announced the appointment of Cannabis Science President & CEO, Raymond C. Dabney as Vice Chair of the newly launched Constituency for Africa (CFA) Africa Healthcare Infrastructure Committee. Mr. Dabney joins Dr. Roscoe M. Moore Jr. (retired US Assistant Surgeon General) who is Interim Chair of CFA and also Chair of the Africa Healthcare Infrastructure Committee, along with 13 others consisting of individuals with extensive experience working in or with Africa in the public and private sectors.

Cannabis Science, Inc. to Release 8 Initial Cannabis-Based Products

Cannabis Science, Inc. announced the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities. The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The roll-out will involve Cannabis Science teams in both Europe and California to work in tandem to share information, send formulations to be produced in each respective production facility and share patient indicators based on usage metrics to scale demand, while collecting insightful data in each geographical market appropriately. Different logistical capabilities will be developed through internal management to adequately produce, distribute and market products along with the proper procurement of opt-in, informed consent patient data from outcomes to establish Cannabis Science with a vertically integrated product pipeline to accommodate international markets. The initial cannabis formulations will be focused on topical formulations for cancers; ingestible formulations for cancers, HIV/AIDS and other indications; varied formulations for neurological disorders and other indications depending on delivery methodology required; ingestible and topical formulations for chemotherapy side effects, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, rheumatism, arthritis, infections, diabetes, manic depression, fibromyalgia and other issues; topical formulations for rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain, radiotherapy wounds, rheumatism, open wounds and sensitive and irritated skin, various skin complaints, and wounds.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBIS:US $0.04 USD +0.0011

CBIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GW Pharmaceuticals PLC 515.00 GBp +20.25
Medical Marijuana Inc $0.10 USD -0.0025
PharmaCyte Biotech Inc $0.14 USD +0.001
View Industry Companies

Industry Analysis


Industry Average

Valuation CBIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,151.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3,287.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANNABIS SCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at